Litifilimab
From Wikipedia - Reading time: 4 min | This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023) |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | BDCA2 |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
Litifilimab is an investigational drug being evaluated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. It is an anti-BDCA2 monocolonal antibody.[1][2][3]
References[edit]
- ^ "Litifilimab - Biogen". AdisInsight. Springer Nature Switzerland AG.
- ^ Cho SK, Vazquez T, Werth VP (May 2023). "Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus". Expert Opinion on Investigational Drugs. 32 (5): 345–353. doi:10.1080/13543784.2023.2212154. PMID 37148249. S2CID 258547912.
- ^ Cho YM, Furie R (October 2023). "The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus". Immunotherapy. doi:10.2217/imt-2023-0086. PMID 37877249. S2CID 264448220.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This article is licensed under CC BY-SA 3.0.
Original source: https://en.wikipedia.org/wiki/Litifilimab
Status: article is cached
Original source: https://en.wikipedia.org/wiki/Litifilimab
Status: article is cached
EncycloReader
is supported by the 
KSF